Peapack Gladstone Financial Corp Has $19.50 Million Stake in Pfizer Inc. (NYSE:PFE)

Peapack Gladstone Financial Corp trimmed its stake in Pfizer Inc. (NYSE:PFE) by 3.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 734,965 shares of the biopharmaceutical company’s stock after selling 28,011 shares during the period. Peapack Gladstone Financial Corp’s holdings in Pfizer were worth $19,499,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. United Bank boosted its holdings in Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the period. Janus Henderson Group PLC boosted its stake in Pfizer by 0.5% during the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock valued at $15,348,000 after purchasing an additional 2,600 shares during the period. Kovitz Investment Group Partners LLC grew its holdings in Pfizer by 35.4% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock valued at $10,612,000 after buying an additional 95,896 shares during the last quarter. Hendershot Investments Inc. grew its holdings in Pfizer by 12.7% in the 3rd quarter. Hendershot Investments Inc. now owns 24,895 shares of the biopharmaceutical company’s stock valued at $720,000 after buying an additional 2,798 shares during the last quarter. Finally, DF Dent & Co. Inc. increased its position in Pfizer by 11.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 4,852 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of PFE stock opened at $22.99 on Friday. The stock’s fifty day simple moving average is $25.87 and its 200 day simple moving average is $26.74. Pfizer Inc. has a one year low of $22.95 and a one year high of $31.54. The firm has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.